These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20170372)

  • 21. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 22. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.
    Dieltjens T; Heyndrickx L; Willems B; Gray E; Van Nieuwenhove L; Grupping K; Vanham G; Janssens W
    Retrovirology; 2009 Dec; 6():113. PubMed ID: 20003438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of nonneutralizing antibodies in vaccines and/or HIV infected individuals.
    Mayr L; Su B; Moog C
    Curr Opin HIV AIDS; 2017 May; 12(3):209-215. PubMed ID: 28422785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.
    Verkoczy L; Kelsoe G; Moody MA; Haynes BF
    Curr Opin Immunol; 2011 Jun; 23(3):383-90. PubMed ID: 21524897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PUBLIC HEALTH. Toward an HIV vaccine: A scientific journey.
    Fauci AS; Marston HD
    Science; 2015 Jul; 349(6246):386-7. PubMed ID: 26206922
    [No Abstract]   [Full Text] [Related]  

  • 26. HIV Immunology Goes Out On a Limb.
    Doria-Rose NA; Mascola JR
    Immunity; 2016 May; 44(5):1088-90. PubMed ID: 27192575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [HIV-1 cell-to-cell transmission and broadly neutralizing antibodies].
    Malbec M; Mouquet H; Schwartz O
    Med Sci (Paris); 2014 May; 30(5):508-10. PubMed ID: 24939535
    [No Abstract]   [Full Text] [Related]  

  • 28. Broadly Neutralizing Antibodies and the Development of Vaccines.
    Haynes BF; Bradley T
    JAMA; 2015 Jun 23-30; 313(24):2419-20. PubMed ID: 26103022
    [No Abstract]   [Full Text] [Related]  

  • 29. Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads.
    Caulfield MJ; Dudkin VY; Ottinger EA; Getty KL; Zuck PD; Kaufhold RM; Hepler RW; McGaughey GB; Citron M; Hrin RC; Wang YJ; Miller MD; Joyce JG
    J Biol Chem; 2010 Dec; 285(52):40604-11. PubMed ID: 20943652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring.
    Zwick MB
    AIDS; 2005 Nov; 19(16):1725-37. PubMed ID: 16227780
    [No Abstract]   [Full Text] [Related]  

  • 31. New center focuses on neutralizing antibodies.
    McEnery R
    IAVI Rep; 2008; 12(5):15. PubMed ID: 20210066
    [No Abstract]   [Full Text] [Related]  

  • 32. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
    Verkoczy L; Kelsoe G; Haynes BF
    PLoS Pathog; 2014 May; 10(5):e1004073. PubMed ID: 24853821
    [No Abstract]   [Full Text] [Related]  

  • 33. Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding.
    Kulp DW; Steichen JM; Pauthner M; Hu X; Schiffner T; Liguori A; Cottrell CA; Havenar-Daughton C; Ozorowski G; Georgeson E; Kalyuzhniy O; Willis JR; Kubitz M; Adachi Y; Reiss SM; Shin M; de Val N; Ward AB; Crotty S; Burton DR; Schief WR
    Nat Commun; 2017 Nov; 8(1):1655. PubMed ID: 29162799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing antibodies and control of HIV: moves and countermoves.
    Hessell AJ; Haigwood NL
    Curr HIV/AIDS Rep; 2012 Mar; 9(1):64-72. PubMed ID: 22203469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The RV144 Thai HIV vaccine trial.
    Plotkin SA
    Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV Vaccination: A Roadmap among Advancements and Concerns.
    Trovato M; D'Apice L; Prisco A; De Berardinis P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Correlate-Guided HIV Vaccine Design.
    Alter G; Barouch D
    Cell Host Microbe; 2018 Jul; 24(1):25-33. PubMed ID: 30001521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
    Kwong PD; Mascola JR
    Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Teaching a Clone to Walk, One Step at a Time.
    Crowe JE
    Cell; 2016 Sep; 166(6):1360-1361. PubMed ID: 27610559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.